LaToya Perry, MD
Dr. LaToya Perry
The University of Oklahoma
800 N E 10th Street #5050
Oklahoma City,
OK
USA
73104
Biographical Sketch: Fellow in training. I have contributed to several studies analyzing the natural history of antiangiogenic agent bevacizumab on the PFI and OS. I have presented on the topic of a modified IP therapy regimen for primary treatement in advanced ovarian cancer.
Papers:
120 - Featured Poster
The influence of obesity on disease characteristics and survival among patients with epithelial ovarian cancer
164 - Poster Session A
Adenocarcinoma indicates more favorable prognosis with cervix cancer
224 - Poster Session A
Characterization of primary platinum resistance in an era of biologic agents and novel chemotherapeutic design
240 - Poster Session A
Venous thromboembolism carries a particularly grave prognosis with epithelial ovarian cancer
251 - Poster Session A
Acquired platinum resistance among women with high-grade serous epithelial ovarian cancer
426 - Poster Session B
The effect of age on completion of prescribed chemoradiation among patients with cervix cancer